Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
AMRN
AMRN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
AMRN News
United Therapeutics Acquires Thymmune Therapeutics to Enhance Regenerative Medicine Pipeline
5d ago
NASDAQ.COM
U.S. Supreme Court Rules in Favor of Hikma Pharmaceuticals
Jun 05 2026
NASDAQ.COM
Supreme Court Backs Hikma's 'Skinny Labels' Ruling Against Amarin
Jun 04 2026
seekingalpha
Amarin Unveils New Cardiovascular Disease Identification Method at EAS Congress
May 28 2026
NASDAQ.COM
Amarin Q1 Earnings Report Analysis
Apr 29 2026
seekingalpha
Amarin Expected to Exceed Q1 Earnings Estimates
Apr 28 2026
seekingalpha
Amarin Faces Challenges, Restructures for Survival
Mar 07 2026
Fool
Amarin Faces Patent Loss and Competitive Pressures
Mar 07 2026
NASDAQ.COM
Amarin Faces Competition and Restructuring Challenges
Mar 07 2026
Yahoo Finance
Amarin's Bleak Prospects vs. Novartis' Strong Investment Appeal
Mar 03 2026
Fool
Amarin Misses Q4 2025 Revenue Forecasts, Shares Drop
Feb 25 2026
seekingalpha
Amarin Q4 Earnings: Revenue Decline but Cash Increases
Feb 25 2026
seekingalpha
Amarin Scheduled to Announce Q4 Earnings on February 25
Feb 24 2026
seekingalpha
Amarin Advances VASCEPA with Over 25 Million Global Prescriptions and New Therapy Insights
Jan 09 2026
Globenewswire
Daily Upgrade Report for Validea Kenneth Fisher Strategy - December 9, 2025
Dec 09 2025
NASDAQ.COM
New Analysis from REDUCE-IT® on Aspirin Unveiled at AHA Scientific Sessions 2025 Confirms VASCEPA®/VAZKEPA® (Icosapent Ethyl) Lowers Cardiovascular Events in High-Risk Individuals
Nov 09 2025
Yahoo Finance
Show More News
